Cutia Therapeutics (2487.HK)

7.350 +0.240 (+3.38%) At close: 04:08PM HKT

Cutia Therapeutics

Huanzhi Building
20th Floor 436 Heng Feng Road Jingan District
Shanghai 200070
China
86 21 5298 2688
https://www.cutiatx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 298

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Lele Zhang	Founder, CEO & Executive Director	4.58M	N/A	1977
Mr. Yuqing Huang	CFO & Executive Director	7.71M	N/A	1990
Mr. Qi Zhu	Chief Medical Officer	N/A	N/A	1973
Dr. Lei Lei	Senior Vice President of Research & Development Department	N/A	N/A	1985
Ms. Chunna Zhang	Senior Vice President of Regulatory Affairs Department	N/A	N/A	1979
Ms. Jingxin Xu	Senior Vice President of Manufacturing & Quality Control Department	N/A	N/A	1979
Mr. Jiaru Wu	Senior Vice President of Finance & Integrated Management Department	N/A	N/A	1984
Ms. Sze Ting Chan A.C.S.	Company Secretary	N/A	N/A	1982

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Cutia Therapeutics an investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People's Republic of China and Hong Kong. It focuses on the dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. The company's products include CU-40102, a topical finasteride spray approved for androgenetic alopecia treatment; CU-10201, a topical 4% minocycline foam, approved for acne vulgaris treatment; and CU-10101, a topical novel small molecule agent, and a non-hormonal and small molecule drug for the treatment of mild to moderate atopic dermatitis. It is also involved in the development of CU-20401, a recombinant mutant collagenase, currently under Phase II clinical trial for submental adipose accumulation (submental fat); CU-40101, a topical small molecule thyroid hormone receptor agonist liniment, currently completed Phase I clinical trial for the treatment of androgenetic alopecia; and CU-30101, a localized topical lidocaine and tetracaine compound topical anesthesia cream, completed Phase III clinical trial for surface dermatologic operations. The company was incorporated in 2019 and is headquartered in Shanghai, China.

Corporate governance

Cutia Therapeutics’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.